理解风湿性多肌痛的免疫病理生理学:对治疗的启示
风湿性多肌痛(PMR)常见于≥50岁人群,以颈部、双侧肩髋带疼痛和晨僵为特征,与巨细胞动脉炎(GCA)和类风湿关节炎共享免疫病理生理机制。糖皮质激素(GC)虽为标准治疗,但超过50%患者无法成功减量,长期使用伴随大量GC相关不良事件。本文综述PMR免疫病理生理学,讨论未满足的医疗需求及靶向治疗选择,如IL-6受体抑制剂。
要点
- PMR与GCA及类风湿关节炎共享免疫病理生理机制,构成GCA-PMR谱系。
- GC为PMR标准治疗,但超过50%患者无法成功减量,长期使用有GC相关不良事件。
- IL-6在PMR免疫病理生理中发挥多种作用,IL-6受体抑制剂等靶向治疗提供有前景的替代选择。
核心结论
- 鉴于IL-6在PMR免疫病理生理中的多种作用,IL-6受体抑制剂等靶向分子疗法为疾病管理提供了有前景的替代选择,不同于GC的非特异性免疫抑制作用。
研究设计与样本
- 本文为综述,描述PMR的免疫病理生理学并讨论未满足的医疗需求及治疗选择。
主要发现
- 基于肩峰下滑囊活检的免疫组织学研究提示,巨噬细胞、IL-6和成纤维样滑膜细胞(FLS)等多种细胞和细胞因子在PMR免疫病理生理中发挥重要作用。
- 包括IL-1、IL-6、IL-17和肿瘤坏死因子α在内的促炎细胞因子激活FLS,FLS随后分泌IL-6,进一步促进FLS增殖。
- 滑囊中滑膜细胞激活可能导致滑囊炎,进而导致急性期反应物高浓度和全身性炎症。
- IL-6还通过破坏下丘脑-垂体-肾上腺轴及作用于外周和中枢疼痛通路,在睡眠障碍、情绪障碍、疼痛和疲劳中发挥作用,这些在PMR中常见。
关键数值与推荐
- GC为PMR标准治疗已数十年(美国风湿病学会/欧洲抗风湿病联盟指南)。
- 超过50%的PMR患者无法成功减量GC。
- 长期GC治疗与大量GC相关不良事件相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polymyalgia rheumatica (PMR) is one of the most common inflammatory rheumatic diseases in people aged ≥50 years and is characterised by neck pain, bilateral shoulder and hip girdle pain, and morning stiffness. It is closely interlinked with giant cell arteritis (GCA) (potentially considered the GCA-PMR spectrum) and rheumatoid arthritis and shares a common immunopathophysiology with both. Glucocorticoids (GCs) have been the standard of care for PMR for several decades (American College of Rheumatology/European Alliance of Associations for Rheumatology guidelines); however, >50% of patients cannot successfully taper GCs, and long-term treatment is associated with considerable GC-related adverse events. Immunohistological studies using biopsies from subacromial bursae have indicated that various cytokines and cells, including macrophages, interleukin-6 (IL-6), and fibroblast-like synoviocytes (FLS), play an integral role in the immunopathophysiology of PMR. Proinflammatory cytokines, including IL-1, IL-6, IL-17, and tumour necrosis factor-alpha, activate FLS which then secrete IL-6 that can further promote FLS proliferation. Activation of synoviocytes in bursae may result in bursitis which can lead to a high concentration of acute-phase reactants and systemic inflammation. IL-6 also plays a role in sleep disturbances, mood disorders, pain, and fatigue; it is often seen in PMR, via disruption of the hypothalamic-pituitary-adrenal axis, and actions on the peripheral and central pain pathways. Given the diverse roles of IL-6 in the immunopathophysiology of PMR, targeted molecular therapies such as IL-6 receptor inhibitors offer promising alternatives for disease management, distinct from the nonspecific immunosuppressive effects of GCs. In this review, we describe the immunopathophysiology of PMR and discuss unmet medical needs and therapeutic options for PMR.
引用
- Choy EH, Unizony SH, Wells AF, et al. Understanding the immunopathophysiology of polymyalgia rheumatica: implications for treatment. Ann Rheum Dis. 2025. PMID: 41107118. doi:10.1016/j.ard.2025.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。